Newsletter Archives
Site Map
|
Johns Hopkins University Study Shows Type II
Diabetics Lost Twice as Much Weight Using Medifast as Those on an
ADA Diet
|
Thursday December 11, 4:13 pm ET
|
OWINGS MILLS, Md., Dec. 11 /PRNewswire-FirstCall/ -- Medifast,
Inc. (Amex: MED - News) is pleased to announce the preliminary
34-week results from its one year and 34-week diabetes study
conducted by the Johns Hopkins Bloomberg School of Health.
ADVERTISEMENT
|
Preliminary results of the study show that those study volunteers
on the Medifast Diet for Diabetics lost twice as much weight as
compared to those following basic nutrition recommendations from
the American Diabetes Association (ADA).
Study results show that those on the Medifast Diet for Diabetics
program lost an average of 16 pounds versus the ADA diet group
that lost an average of 8 pounds. Additionally, two-thirds of
those on the Medifast program lost at least 5% of their weight,
which is a standard measure of the Federal Drug Administration's
(FDA) threshold to indicate clinically significant weight loss,
versus one-quarter of those on the ADA diet.
Compliance data indicates that almost twice as many people on the
Medifast program were able to complete the weight loss portion of
the study.
"These results suggest that the Medifast diet was easier to adhere
to than the comparison diet," says Dr. Larry Cheskin, the
principal investigator and Hopkins study examiner. "These results
may be important for people who are overweight and have Type II
Diabetes. We're telling people they need to lose weight and manage
their diet or risk serious health consequences, so it is useful to
study what weight loss method is most effective."
Medifast asked Dr. Cheskin to conduct a study after receiving
numerous reports from patients that Medifast products helped
control their diabetes symptoms.
"I have been a diabetic for about five or six years. As of today I
am completely off all my sugar and cholesterol medications and my
blood pressure is normal. My total weight loss on this program has
been 50 pounds. I'll tell you; this has made the difference to me
in life and death. I truly believe Medifast has been a miracle in
my life," says Josephine Shaw, a diabetic patient who worked
closely with Medifast's Medical Director, Dr. Wayne Andersen.
"In my twenty years as a critical care physician using surgery and
medicines, I have never experienced the amazing improvement in
disease that I have in the two years we have been focused on
nutritional intervention as the first line defense against
disease," says Dr. Andersen. "Within 4 to 16 weeks our patients
are coming off their cholesterol and diabetic medication and
showing dramatic improvements in the symptomentology of several
other conditions."
The researchers randomized two groups of Type II diabetic
volunteers. One group was given the Medifast Plus for Diabetics
defined-formula meal replacement diet of soups, oatmeal, bars and
a variety of shakes. The other group was asked to follow a diet
based on ADA nutrition guidelines, shop for their own food and
manage their own portions, but had the same guidance from the
doctors, counselors and dietitians in the study as the Medifast
group.
The study found those randomized to the Medifast program had an
average 7.5% decrease in body fat, a clinically significant
amount.
In addition to weight loss, the initial study results are that
Medifast participants sustained an average 9% decrease in blood
fasting glucose and an average 19% decrease in insulin levels.
Medifast participants also achieved an average 12% decrease in
fasting triglycerides, and an average 9% increase in HDL (good)
cholesterol. Their levels of systolic and diastolic blood pressure
decreased significantly.
What's more, a number of patients in the Medifast group were able
to significantly reduce the number and dose of their medicines.
Participants on the Medifast diet saw an average of 27%
improvement in their Health Related Quality of Life, which
measures such things as physical functioning, energy levels and
general health.
"Until now, drug therapy has been the gold standard for diabetics.
These results suggest that nutritional therapy could be more
effective early on, reduce cost and provide better health for
diabetics," said Brad MacDonald, Medifast's CEO.
"If diabetics are being told to lose weight, initial results show
that they may be better off on a portion controlled,
defined-formula diet," said Dr. Cheskin. "This is important
information for Type II diabetics seeking weight loss."
This release contains forward-looking statements, which may
involve known and unknown risks, uncertainties and other factors
that may cause Medifast's actual results and performance in future
periods to be materially different from any future results or
performance suggested by these statements. Medifast cautions
investors not to place undue reliance on forward-looking
statements, which speak only to management's expectation on this
date.
|
More News
|
|